This Lab brought together a diverse group of more than 40 medical research and financial experts from biotechnology and pharmaceutical companies, medical research foundations, venture capital, and private equity firms, academic and entrepreneurial institutions, and credit agencies. Our objective was to explore innovative financial strategies that could increase access to capital for translational research. The group discussed and debated various approaches for managing and financing translational research, including:

• Virtual product/portfolio development companies

• Venture philanthropy and government-backed investment vehicles

• Innovative investor tax incentives

• Securitized research-based obligations